X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (23) 23
humans (21) 21
cardiac & cardiovascular systems (15) 15
female (15) 15
abridged index medicus (13) 13
male (13) 13
middle aged (12) 12
aged (11) 11
myocardial infarction (8) 8
risk factors (8) 8
care and treatment (7) 7
prevention (7) 7
stroke (7) 7
ticagrelor (7) 7
treatment outcome (7) 7
cardiovascular disease (6) 6
dosage and administration (6) 6
double-blind method (6) 6
health aspects (6) 6
mortality (6) 6
obesity (6) 6
peripheral vascular disease (6) 6
adenosine - analogs & derivatives (5) 5
analysis (5) 5
clopidogrel (5) 5
exercise (5) 5
follow-up studies (5) 5
heart attacks (5) 5
heart failure (5) 5
hemorrhage - chemically induced (5) 5
risk (5) 5
secondary prevention (5) 5
usage (5) 5
acute coronary syndromes (4) 4
adenosine - administration & dosage (4) 4
adenosine - adverse effects (4) 4
aspirin (4) 4
atrial fibrillation (4) 4
body mass index (4) 4
cardiovascular diseases (4) 4
child (4) 4
clinical trials (4) 4
coronary artery disease (4) 4
diabetes (4) 4
drug therapy (4) 4
heart attack (4) 4
internal medicine (4) 4
management (4) 4
myocardial infarction - drug therapy (4) 4
overweight (4) 4
physical activity (4) 4
prevalence (4) 4
purinergic p2y receptor antagonists - administration & dosage (4) 4
research (4) 4
united-states (4) 4
warfarin (4) 4
adolescents (3) 3
anticoagulants (3) 3
behavior (3) 3
beverages (3) 3
confidence intervals (3) 3
diet (3) 3
disease (3) 3
dose-response relationship, drug (3) 3
drug administration schedule (3) 3
guidelines (3) 3
health behavior (3) 3
health promotion (3) 3
heart diseases (3) 3
language arts (3) 3
medicine, general & internal (3) 3
myocardial-infarction (3) 3
physical-activity (3) 3
purinergic p2y receptor antagonists - adverse effects (3) 3
pyridines - adverse effects (3) 3
safety (3) 3
statin therapy (3) 3
stroke - prevention & control (3) 3
therapy (3) 3
time factors (3) 3
adenosine - pharmacokinetics (2) 2
adenosine-diphosphate (2) 2
adult (2) 2
adults (2) 2
aged, 80 and over (2) 2
anticoagulation (2) 2
antiplatelet therapy (2) 2
arteriosclerosis (2) 2
artery-disease (2) 2
association (2) 2
atrial fibrillation - complications (2) 2
biomarker (2) 2
blood platelets - drug effects (2) 2
body weight (2) 2
body-mass index (2) 2
cardiac and cardiovascular systems (2) 2
cardiology (2) 2
cardiorespiratory fitness (2) 2
cardiovascular (2) 2
cardiovascular diseases - complications (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 05/2017, Volume 376, Issue 18, pp. 1713 - 1722
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2019, Volume 380, Issue 4, pp. 347 - 357
In a randomized trial of patients with type 2 diabetes, treatment with dapagliflozin, an SGLT2 inhibitor that promotes glucosuria, did not result in a higher... 
2013 ACCF/AHA GUIDELINE | MEDICINE, GENERAL & INTERNAL | SELECTIVE SGLT2 INHIBITOR | MANAGEMENT | HEART-FAILURE OUTCOMES | DISEASE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | KIDNEY | EMPAGLIFLOZIN | SOCIETY | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Type 2 diabetes | Safety and security measures | Dapagliflozin | Dosage and administration | Drug therapy | Cardiovascular diseases | Risk factors | Heart failure | Myocardial infarction | Cerebral infarction | End-stage renal disease | Heart attacks | Mortality | Diabetes mellitus | Cardiovascular disease | FDA approval | Patients | Glomerular filtration rate | Heart rate | Ischemia | Sodium | Arteriosclerosis | Ketoacidosis | Death | Diabetes | Kidney diseases | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 07/2016, Volume 134, Issue 1, pp. 24 - 36
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2016, Volume 67, Issue 10, pp. 1145 - 1154
Journal Article
JAMA, ISSN 0098-7484, 04/2016, Volume 315, Issue 15, pp. 1591 - 1599
IMPORTANCE: p38 Mitogen-activated protein kinase (MAPK)–stimulated inflammation is implicated in atherogenesis, plaque destabilization, and maladaptive... 
Recurrence | Myocardial Infarction - mortality | Humans | Middle Aged | Male | Secondary Prevention | Cyclopropanes - adverse effects | Protein Kinase Inhibitors - adverse effects | Cyclopropanes - therapeutic use | Pyridines - adverse effects | Treatment Failure | Female | C-Reactive Protein - analysis | Myocardial Infarction - enzymology | Pyridines - therapeutic use | Double-Blind Method | Drug Administration Schedule | Myocardial Ischemia - prevention & control | Hospitalization | Myocardial Revascularization | Algorithms | Myocardial Infarction - drug therapy | Protein Kinase Inhibitors - therapeutic use | p38 Mitogen-Activated Protein Kinases - antagonists & inhibitors | Aged | Myocardial Ischemia - surgery | Clinical trials | Care and treatment | Usage | Dosage and administration | Extracellular signal-regulated kinases | Heart attack | Patient safety | Inhibitor drugs | Heart attacks | Clinical outcomes | Index Medicus | Abridged Index Medicus | Pyridines/adverse effects/therapeutic use | Cyclopropanes/adverse effects/therapeutic use | C-Reactive Protein/analysis | Klinisk medicin | Clinical Medicine | p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors | Myocardial Ischemia/prevention & control/surgery | Protein Kinase Inhibitors/adverse effects/therapeutic use | Myocardial Infarction/drug therapy/enzymology/mortality
Journal Article